Drug-Induced Liver Injury: Biomarkers, Requirements, Candidates, and Validation
The hepatotoxicity of drugs is the main cause of drug withdrawal from the pharmaceutical market and interruption of the development of new molecules. Biomarkers are useful in several situations. In case of suspected drug-induced liver injury (DILI), biomarkers can be used to confirm liver damage, it...
Saved in:
Main Authors: | Lucy Meunier (Author), Dominique Larrey (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Immunotherapy and Gene Therapy: New Challenges in the Diagnosis and Management of Drug-Induced Liver Injury
by: Bénédicte Delire, et al.
Published: (2022) -
The Immunological Mechanisms and Immune-Based Biomarkers of Drug-Induced Liver Injury
by: Wenhui Liu, et al.
Published: (2021) -
Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives
by: Siyu Fu, et al.
Published: (2020) -
Astaxanthin effect on apoptotic biomarkers in methotrexate-induced liver injury
by: Sarah Saad Hamdan, et al.
Published: (2022) -
Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
by: Marina Villanueva-Paz, et al.
Published: (2021)